Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.
Metastatic Castration-resistant Prostate Cancer
DRUG: TABP EIC|BIOLOGICAL: Cyclophosphamide|BIOLOGICAL: fludarabine
Occurrence of treatment related adverse events as assessed by CTCAE v5.0, Defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment, Baseline to 1 year post infusion
The pharmacokinetic analysis of TABP EIC, Changes in the number of CD56+/ CD3-TABP EIC in peripheral blood over time, D0, D1, D3, D7, D8, D10, D14, D15, D17, D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion|The pharmacodynamics analysis of TABP EIC, Changes of total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) in peripheral blood, Baseline to infusion date, D28±1, D60±2, D120±2, D180±7, D270±7, 和 D365±7|The proportion of patients with a decrease in PSA levels from baseline., PSA response rate, Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion|Progression-free survival (PFS) after TABPEIC infusion, Survival time of patients, Baseline to 1 year post infusion|Time to clinical progression, The time from baseline to the appearance of increased PSA levels or imaging progression., Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.